Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

119.04USD
22 Sep 2017
Change (% chg)

$0.37 (+0.31%)
Prev Close
$118.67
Open
$118.60
Day's High
$119.60
Day's Low
$116.75
Volume
152,706
Avg. Vol
402,400
52-wk High
$192.94
52-wk Low
$96.52

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $6,449.70
Shares Outstanding(Mil.): 54.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

Tesaro's ovarian cancer drug gets EU agency backing

A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Sep 15 2017

Tesaro's ovarian cancer drug gets EU agency backing

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Sep 15 2017

BRIEF-Tesaro Inc Q2 loss per share $2.82

* Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S

Aug 08 2017

BRIEF-Tesaro sale process seen unlikely to result in a deal - CNBC

* Tesaro Inc sale process seen unlikely to result in a deal - CNBC, citing sources Further company coverage:

Jul 13 2017

Clovis's ovarian cancer drug set for label expansion, shares soar

Clovis Oncology Inc said on Monday late-stage data on its already-approved ovarian cancer drug showed that the treatment could benefit four times as many patients, sending shares of the U.S. biotech soaring 50 percent.

Jun 19 2017

UPDATE 4-Clovis's ovarian cancer drug set for label expansion, shares soar

* Rival Tesaro's shares slip 3 pct (Adds analyst comment; updates shares)

Jun 19 2017

RPT-BRIEF-Tesaro Inc is exploring a sale, asked for initial bids - CNBC, citing DJ

* Tesaro shares soar more than 10 percent after DJ reports co is exploring a sale, asked for initial bids - CNBC, citing DJ Source text: http://on.wsj.com/2rc8WqL Further company coverage:

May 31 2017

BRIEF-Tesaro Inc is exploring a sale, asked for initial bids - CNBC

* Tesaro shares soar more than 10 percent after DJ reports co is exploring a sale, asked for initial bids - CNBC, citing DJ Further company coverage:

May 31 2017

BRIEF-Tesaro reports Q1 loss per share $2.55

* Q1 earnings per share view $-2.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA

* TESARO announces submission of investigational new drug application for anti-lag antibody tsr-033 to the u.s. Fda

May 01 2017

Earnings vs. Estimates